ArchiveJune 2015

Alemtuzumab, here I come: Top line results of the Ocrelizumab in relapsing MS studies

This morning, Roche announced the headline results of their Ocrelizumab in relapsing MS program (OPERA I and II).   Here is their press release: Numerous posts on this blog have highlighted the potential of this humanized version of Rituximab (check the “BartsMS essential off-label DMT list” in the left upper corner), an established drug to treat people with B cell lymphoma...

Vitamin D in Optic Neuritis Trial fails

Salari M, Janghorbani M, Etemadifar M, Dehghani A, Razmjoo H, Naderian G.Effects of vitamin D on retinal nerve fiber layer in vitamin D deficient patients with optic neuritis: Preliminary findings of a randomized, placebo-controlled trial.J Res Med Sci. 2015;20(4):372-8 BACKGROUND:There is accumulating evidence for a possible protective role of vitamin D in the development and disease course of...

The US experience of natalizumab – both very telling and very important to tell

CNS Drugs. 2015 Jun 26. [Epub ahead of print] Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients. Johnson BH, Bonafede MM, Watson C. BACKGROUND: Multiple sclerosis (MS) registry data, primarily from Europe, suggest that treatment with natalizumab delays time to relapse compared with platform therapy...

Brain lymphatics are like buses wait fifty years and two papers come all in a short space of time

Aspelund A, Antila S, Proulx ST, Karlsen TV, Karaman S, Detmar M, Wiig H, Alitalo K. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med. 2015 . pii: jem.20142290. [Epub ahead of print] The central nervous system (CNS) is considered an organ devoid of lymphatic vasculature. Yet, part of the cerebrospinal fluid (CSF) drains into the cervical lymph...

New prescribing guidelines for multiple sclerosis

Scolding N et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis Pract Neurol 2015 The Association of British Neurologists (ABN) revised prescribing guidelines for the treatment of relapsing-remitting MS (RRMS) have been published. MS charities had the opportunity to comment on the revisions and...

MS Frontiers 2015

This is the biennial Science meeting  on behalf of the MS Society in the UK. This is held at Heathrow Airport.  However, if you want to see what’s going on CLICK HERE Follow on twitter #MSfroniters                                           The Debate:   ...

CD40 reduction in MS

Field J, Shahijanian F, Schibeci S; Australia and New Zealand MS Genetics Consortium (ANZgene), Johnson L, Gresle M, Laverick L, Parnell G, Stewart G, McKay F, Kilpatrick T, Butzkueven H, Booth D. The MS Risk Allele of CD40 Is Associated with Reduced Cell-Membrane Bound Expression in Antigen Presenting Cells: Implications for Gene Function. PLoS One. 2015 Jun 11;10(6):e0127080 Human...

NF kappa B signalling…a key to controlling inflammation

Housley WJ, Fernandez SD, Vera K, Murikinati SR, Grutzendler J, Cuerdon N, Glick L, De Jager PL, Mitrovic M, Cotsapas C, Hafler DA.Genetic variants associated with autoimmunity drive NFκB signaling and responses to inflammatory stimuli. Sci Transl Med. 2015;7(291):291ra93 The transcription factor nuclear factor κB (NFκB) is a central regulator of inflammation, and genome-wide association studies...

Another deficit in the immune response of MSers

Dhaeze T, Peelen E, Hombrouck A, Peeters L, Van Wijmeersch B, Lemkens N, Lemkens P, Somers V, Lucas S, Broux B, Stinissen P, Hellings N. Circulating Follicular Regulatory T Cells Are Defective in Multiple Sclerosis. J Immunol. 2015 Jun 12. pii: 1500759. [Epub ahead of print] Follicular regulatory T cells (TFR) have been extensively characterized in mice and participate in germinal center...

Translate

Categories

Recent Posts

Recent Comments

Archives